Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).


Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
Jun 2022
Historique:
received: 06 07 2021
accepted: 20 10 2021
pubmed: 17 11 2021
medline: 11 5 2022
entrez: 16 11 2021
Statut: ppublish

Résumé

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) leads to prolonged survival for selected patients with colorectal (CRC) peritoneal metastases (PM). This study aimed to analyze the prognostic role of micro-satellite (MS) status and RAS/RAF mutations for patients treated with CRS. Data were collected from 13 Italian centers with PM expertise within a collaborative group of the Italian Society of Surgical Oncology. Clinical and pathologic variables and KRAS/NRAS/BRAF mutational and MS status were correlated with overall survival (OS) and disease-free survival (DFS). The study enrolled 437 patients treated with CRS-HIPEC. The median OS was 42.3 months [95% confidence interval (CI), 33.4-51.2 months], and the median DFS was 13.6 months (95% CI, 12.3-14.9 months). The local (peritoneal) DFS was 20.5 months (95% CI, 16.4-24.6 months). In addition to the known clinical factors, KRAS mutations (p = 0.005), BRAF mutations (p = 0.01), and MS status (p = 0.04) were related to survival. The KRAS- and BRAF-mutated patients had a shorter survival than the wild-type (WT) patients (5-year OS, 29.4% and 26.8% vs 51.5%, respectively). The patients with micro-satellite instability (MSI) had a longer survival than the patients with micro-satellite stability (MSS) (5-year OS, 58.3% vs 36.7%). The MSI/WT patients had the best prognosis. The MSS/WT and MSI/mutated patients had similar survivals, whereas the MSS/mutated patients showed the worst prognosis (5-year OS, 70.6%, 48.1%, 23.4%; p = 0.0001). In the multivariable analysis, OS was related to the Peritoneal Cancer Index [hazard ratio (HR), 1.05 per point], completeness of cytoreduction (CC) score (HR, 2.8), N status (HR, 1.6), signet-ring (HR, 2.4), MSI/WT (HR, 0.5), and MSS/WT-MSI/mutation (HR, 0.4). Similar results were obtained for DFS. For patients affected by CRC-PM who are eligible for CRS, clinical and pathologic criteria need to be integrated with molecular features (KRAS/BRAF mutation). Micro-satellite status should be strongly considered because MSI confers a survival advantage over MSS, even for mutated patients.

Sections du résumé

BACKGROUND BACKGROUND
Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) leads to prolonged survival for selected patients with colorectal (CRC) peritoneal metastases (PM). This study aimed to analyze the prognostic role of micro-satellite (MS) status and RAS/RAF mutations for patients treated with CRS.
METHODS METHODS
Data were collected from 13 Italian centers with PM expertise within a collaborative group of the Italian Society of Surgical Oncology. Clinical and pathologic variables and KRAS/NRAS/BRAF mutational and MS status were correlated with overall survival (OS) and disease-free survival (DFS).
RESULTS RESULTS
The study enrolled 437 patients treated with CRS-HIPEC. The median OS was 42.3 months [95% confidence interval (CI), 33.4-51.2 months], and the median DFS was 13.6 months (95% CI, 12.3-14.9 months). The local (peritoneal) DFS was 20.5 months (95% CI, 16.4-24.6 months). In addition to the known clinical factors, KRAS mutations (p = 0.005), BRAF mutations (p = 0.01), and MS status (p = 0.04) were related to survival. The KRAS- and BRAF-mutated patients had a shorter survival than the wild-type (WT) patients (5-year OS, 29.4% and 26.8% vs 51.5%, respectively). The patients with micro-satellite instability (MSI) had a longer survival than the patients with micro-satellite stability (MSS) (5-year OS, 58.3% vs 36.7%). The MSI/WT patients had the best prognosis. The MSS/WT and MSI/mutated patients had similar survivals, whereas the MSS/mutated patients showed the worst prognosis (5-year OS, 70.6%, 48.1%, 23.4%; p = 0.0001). In the multivariable analysis, OS was related to the Peritoneal Cancer Index [hazard ratio (HR), 1.05 per point], completeness of cytoreduction (CC) score (HR, 2.8), N status (HR, 1.6), signet-ring (HR, 2.4), MSI/WT (HR, 0.5), and MSS/WT-MSI/mutation (HR, 0.4). Similar results were obtained for DFS.
CONCLUSION CONCLUSIONS
For patients affected by CRC-PM who are eligible for CRS, clinical and pathologic criteria need to be integrated with molecular features (KRAS/BRAF mutation). Micro-satellite status should be strongly considered because MSI confers a survival advantage over MSS, even for mutated patients.

Identifiants

pubmed: 34783946
doi: 10.1245/s10434-021-11045-3
pii: 10.1245/s10434-021-11045-3
doi:

Substances chimiques

Proto-Oncogene Proteins B-raf EC 2.7.11.1
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3405-3417

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2021. Society of Surgical Oncology.

Références

Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144:1941–53.
pubmed: 30350310 doi: 10.1002/ijc.31937
Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.
pubmed: 22162570 doi: 10.1200/JCO.2011.37.1039
Quere P, Facy O, Manfredi S, Jooste V, Faivre J, Lepage C, et al. Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: a population-based study. Dis Colon Rectum. 2015;58:743–52.
pubmed: 26163953 doi: 10.1097/DCR.0000000000000412
Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709–19.
pubmed: 27743922 doi: 10.1016/S1470-2045(16)30500-9
Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545–50.
pubmed: 12445064 doi: 10.1046/j.1365-2168.2002.02274.x
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;15(21):3737–43.
doi: 10.1200/JCO.2003.04.187
Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681–5.
pubmed: 19103728 doi: 10.1200/JCO.2008.19.7160
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–422.
pubmed: 27380959 doi: 10.1093/annonc/mdw235
Quénet F, Elias D, Roca L, Goéré D, Ghouti L, Pocard M, et al.; UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:256–66. https://doi.org/10.1016/S1470-2045(20)30599-4 .
Hallam S, Tyler R, Price M, Beggs A, Youssef H. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. BJS Open. 2019;3:585–94.
pubmed: 31592510 pmcid: 6773657 doi: 10.1002/bjs5.50179
Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of RAS gene mutations in human colorectal cancers. Nature. 1987;327:293–7.
pubmed: 3587348 doi: 10.1038/327293a0
Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.
pubmed: 12198537 doi: 10.1038/418934a
Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619–26 (discussion 26–7).
pubmed: 24018645 doi: 10.1097/SLA.0b013e3182a5025a
Gillern SM, Chua TC, Stojadinovic A, et al. KRAS status in patients with colorectal cancer peritoneal carcinomatosis and its impact on outcome. Am J Clin Oncol. 2010;33:456–60.
pubmed: 19952717 doi: 10.1097/COC.0b013e3181b4b160
Bonnot PE, Passot G. RAS mutation: site of disease and recurrence pattern in colorectal cancer. Chin Clin Oncol. 2019;8:55.
pubmed: 31597436 doi: 10.21037/cco.2019.08.11
Schneider MA, Eden J, Pache B, et al. Mutations of RAS/ RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg. 2018;268:845–53.
pubmed: 30303876 doi: 10.1097/SLA.0000000000002899
Arjona-Sanchez A, Rodriguez-Ortiz L, Baratti D, et al. RAS mutation decreases overall survival after optimal cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of colorectal peritoneal metastasis: a modification proposal of the peritoneal surface disease severity score. Ann Surg Oncol. 2019;26:2595–604.
pubmed: 31111351 doi: 10.1245/s10434-019-07378-9
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.
pubmed: 26028255 pmcid: 4481136 doi: 10.1056/NEJMoa1500596
Morse MA, Hochster H, Benson A. Perspectives on treatment of metastatic colorectal cancer with immune checkpoint inhibitor therapy. Oncologist. 2020;25:33–45.
pubmed: 31383813 doi: 10.1634/theoncologist.2019-0176
Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–18.
pubmed: 15659508 doi: 10.1200/JCO.2005.01.086
Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies. Clin Cancer Res. 2014;20:5322–30.
pubmed: 25139339 pmcid: 4201568 doi: 10.1158/1078-0432.CCR-14-0332
Smith CG, Fisher D, Claes B, Maughan TS, Idziaszczyk S, Peuteman G, et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clin Cancer Res. 2013;19:4104–13.
pubmed: 23741067 pmcid: 3732482 doi: 10.1158/1078-0432.CCR-12-2581
Massalou D, Benizri E, Chevallier A, et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg. 2017;213:377–87.
pubmed: 27816197 doi: 10.1016/j.amjsurg.2016.03.008
Sinicrope FA, Shi Q, Allegra CJ, et al. Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers: a secondary analysis of 2 randomized clinical trials. JAMA Oncol. 2017;3:472.
pubmed: 28006055 pmcid: 5498991 doi: 10.1001/jamaoncol.2016.5469
Sugarbaker PH. Peritoneal carcinomatosis: natural history and rational therapeutic interventions using intraperitoneal chemotherapy. Cancer Treat Res. 1996;81:149–68.
pubmed: 8834582 doi: 10.1007/978-1-4613-1245-1_13
Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: PH Sugarbaker, editor. Peritoneal carcinomatosis: principles of management cancer treatment and research, vol 82, Boston: Springer; 1996.
Baas JM, Krens LL, Guchelaar HJ, et al. Concordance of predictive markers for EGFR inhibitors in primary tumors and metastases in colorectal cancer: a review. Oncologist. 2011;16:1239–49.
pubmed: 21742964 pmcid: 3228174 doi: 10.1634/theoncologist.2011-0024
Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012;30:2956–62.
pubmed: 22665543 pmcid: 3417049 doi: 10.1200/JCO.2011.38.2994
Oliner K, Juan T, Suggs S, Wolf M, Sarosi I, Freeman DJ, et al. A comparability study of 5 commercial KRAS tests. Diagn Pathol. 2010;5:23.
pubmed: 20398393 pmcid: 2879238 doi: 10.1186/1746-1596-5-23
Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314:268–74.
pubmed: 16959974 doi: 10.1126/science.1133427
Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–13.
pubmed: 17932254 doi: 10.1126/science.1145720
Sundström M, Edlund K, Lindell M, et al. KRAS analysis in colorectal carcinoma: analytical aspects of pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer. 2010;10:660.
pubmed: 21122130 pmcid: 3002357 doi: 10.1186/1471-2407-10-660
Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A, Schneider-Stock R. KRAS mutation detection in colorectal cancer using the pyrosequencing technique. Pathol Res Pract. 2007;203:489–97.
pubmed: 17629419 doi: 10.1016/j.prp.2007.06.001
Lewandowska MA, Jóźwicki W, Żurawski B. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells. Mol Diagn Ther. 2013;17:193–203.
pubmed: 23606169 pmcid: 3663254 doi: 10.1007/s40291-013-0025-8
Nagakubo Y, Hirotsu Y, Amemiya K, Oyama T, Mochizuki H, Omata M. Accurate detection of KRAS, NRAS, and BRAF mutations in metastatic colorectal cancers by bridged nucleic acid-clamp real-time PCR. BMC Med Genom. 2019;12:162.
doi: 10.1186/s12920-019-0610-8
Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–57.
pubmed: 9823339
Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, et al. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomark Prev. 2007;16:2331–43.
doi: 10.1158/1055-9965.EPI-07-0648
Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20:1043–8.
pubmed: 11844828 doi: 10.1200/JCO.2002.20.4.1043
Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10:293–300.
pubmed: 18556767 pmcid: 2438196 doi: 10.2353/jmoldx.2008.080031
Buhard O, Cattaneo F, Wong YF, Yim SF, Friedman E, Flejou JF, et al. Multipopulation analysis of polymorphisms in five mononucleotide repeats used to determine the microsatellite instability status of human tumors. J Clin Oncol. 2006;24:241–51.
pubmed: 16330668 doi: 10.1200/JCO.2005.02.7227
Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika. 1993;80:557–72. https://doi.org/10.1093/biomet/80.3.557 .
doi: 10.1093/biomet/80.3.557
Chicago Consensus Working Group. The Chicago consensus on peritoneal surface malignancies: management of colorectal metastases. Ann Surg Oncol. 2020;27:1761–7.
doi: 10.1245/s10434-020-08315-x
Bushati M, Rovers KP, Sommariva A, et al. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol. 2018;44:1942–8.
pubmed: 30075978 doi: 10.1016/j.ejso.2018.07.003
Klaver CE, Groenen H, Morton DG, et al. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis. 2017;19:224–36.
pubmed: 28008728 doi: 10.1111/codi.13593
Mohamed F, Kallioinen M, Braun M, et al. Management of colorectal cancer metastases to the liver, lung, or peritoneum suitable for curative intent: summary of NICE guidance. Br J Surg. 2020;107:943–5.
pubmed: 32386092 doi: 10.1002/bjs.11609
Faron M, Macovei R, Goéré D, et al. Linear relationship of Peritoneal Cancer Index and Survival in patients with peritoneal metastases from colorectal cancer. Ann Surg Oncol. 2016;23:114–9.
pubmed: 26014158 doi: 10.1245/s10434-015-4627-8
Klaver YL, Simkens LH, Lemmens VE, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38:617–23.
pubmed: 22572106 doi: 10.1016/j.ejso.2012.03.008
Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008;26:4906–11.
pubmed: 18794541 doi: 10.1200/JCO.2008.17.3781
Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938–46.
pubmed: 9060531 doi: 10.1200/JCO.1997.15.3.938
Lee RM, Cardona K, Russell MC. Historical perspective: two decades of progress in treating metastatic colorectal cancer. J Surg Oncol. 2019;119:549–63.
pubmed: 30806493 doi: 10.1002/jso.25431
Jegatheeswaran S, Mason JM, Hancock HC, Siriwardena AK. The liver-first approach to the management of colorectal cancer with synchronous hepatic metastases: a systematic review. JAMA Surg. 2013;148:385–91.
pubmed: 23715907 doi: 10.1001/jamasurg.2013.1216
Allard MA, Adam R, Giuliante F, et al. Long-term outcomes of patients with 10 or more colorectal liver metastases. Br J Cancer. 2017;117:604–11.
pubmed: 28728167 pmcid: 5572175 doi: 10.1038/bjc.2017.218
Moran BJ. PROPHYLOCHIP: no benefit of second-look surgery plus HIPEC for colorectal peritoneal metastases. Lancet Oncol. 2020;21:1124–5.
pubmed: 32717181 doi: 10.1016/S1470-2045(20)30338-7
Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers AGJ, et al; COLOPEC Collaborators Group. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol. 2019;4:761–70.
van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230–40.
pubmed: 29342393 doi: 10.1056/NEJMoa1708618
Rovers KP, Simkens GA, Punt CJ, et al. Perioperative systemic therapy for resectable colorectal peritoneal metastases: sufficient evidence for its widespread use? A critical systematic review. Crit Rev Oncol Hematol. 2017;114:53–62.
pubmed: 28477747 doi: 10.1016/j.critrevonc.2017.03.028
Beal EW, Suarez-Kelly LP, Kimbrough CW, et al. Impact of neoadjuvant chemotherapy on the outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: a multi-institutional retrospective review. J Clin Med. 2020;9:748.
pmcid: 7141272 doi: 10.3390/jcm9030748
Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16:1306–15.
pubmed: 26338525 doi: 10.1016/S1470-2045(15)00122-9
Bhatt A, Rousset P, Benzerdjeb N, Kammar P, Mehta S, Parikh L, et al. Prospective correlation of the radiological, surgical and pathological findings in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: implications for the preoperative estimation of the peritoneal cancer index. Colorectal Dis. 2020;22:2123–32.
pubmed: 32940414 doi: 10.1111/codi.15368
van Oudheusden TR, Braam HJ, Luyer MD, Wiezer MJ, van Ramshorst B, Nienhuijs SW, de Hingh IH. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis. Ann Surg Oncol. 2015;22:1236–42.
pubmed: 25319584 doi: 10.1245/s10434-014-4148-x
van Oudheusden TR, Braam HJ, Nienhuijs SW, Wiezer MJ, van Ramshorst B, Luyer P, de Hingh IH. Poor outcome after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis with signet ring cell histology. J Surg Oncol. 2015;111:237–42.
pubmed: 25195780 doi: 10.1002/jso.23784
Simkens GA, Razenberg LG, Lemmens VE, Rutten HJ, Creemers GJ, de Hingh IH. Histological subtype and systemic metastases strongly influence treatment and survival in patients with synchronous colorectal peritoneal metastases. Eur J Surg Oncol. 2016;42:794–800.
pubmed: 27055946 doi: 10.1016/j.ejso.2016.03.014
Razenberg LG, van Gestel YR, Lemmens VE, de Wilt JH, Creemers GJ, de Hingh IH. The prognostic relevance of histological subtype in patients with peritoneal metastases from colorectal cancer: a nationwide population-based study. Clin Colorectal Cancer. 2015;14:e13–9.
pubmed: 26140733 doi: 10.1016/j.clcc.2015.05.011
De Roock W, De Vriendt V, Normanno N, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011;12:594–603.
pubmed: 21163703 doi: 10.1016/S1470-2045(10)70209-6
Allegra CJ, Rumble RB, Hamilton SR, et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016;34:179–85.
pubmed: 26438111 doi: 10.1200/JCO.2015.63.9674
Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.
pubmed: 21502544 doi: 10.1200/JCO.2010.33.5091
Italiano A, Hostein I, Soubeyran I, et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol. 2010;17:1429–34.
pubmed: 20049644 doi: 10.1245/s10434-009-0864-z
Kadowaki S, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, et al. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World J Gastroenterol. 2015;21:1275–83.
pubmed: 25632202 pmcid: 4306173 doi: 10.3748/wjg.v21.i4.1275
Passot G, Kim BJ, Glehen O, et al. Impact of RAS mutations in metastatic colorectal cancer after potentially curative resection: Does site of metastases matter? Ann Surg Oncol. 2018;25:179–87.
pubmed: 29071660 doi: 10.1245/s10434-017-6141-7
Ooki A, Akagi K, Yatsuoka T, Asayama M, Hara H, Takahashi A, et al. Combined microsatellite instability and BRAF gene status as biomarkers for adjuvant chemotherapy in stage III colorectal cancer. J Surg Oncol. 2014;110:982–8.
pubmed: 25154726 doi: 10.1002/jso.23755
Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009;45:1890–6.
pubmed: 19427194 doi: 10.1016/j.ejca.2009.04.018
Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol. 2015;26:126–32.
pubmed: 25361982 doi: 10.1093/annonc/mdu499
Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266–73.
pubmed: 19165197 pmcid: 2634718 doi: 10.1038/sj.bjc.6604867
Haddad R, Ogilvie RT, Croitoru M, Muniz V, Gryfe R, Pollet A, et al. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. Ann Surg Oncol. 2004;11:977–82.
pubmed: 15525826 doi: 10.1245/ASO.2004.03.585
Melloni G, Doglioni C, Bandiera A, Carretta A, Ciriaco P, Arrigoni G, Zannini P. Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinoma. Ann Thorac Surg. 2006;81:2008–13.
pubmed: 16731121 doi: 10.1016/j.athoracsur.2006.01.007
Fujiyoshi K, Yamamoto G, Takenoya T, et al. Metastatic pattern of stage IV colorectal cancer with high-frequency microsatellite instability as a prognostic factor. Anticancer Res. 2017;37:239–47.
pubmed: 28011498 doi: 10.21873/anticanres.11313
Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer. 2013;108:1757–64.
pubmed: 23511557 pmcid: 3668469 doi: 10.1038/bjc.2013.118
Vilar E, Gruber SB. Microsatellite instability in colorectal cancer: the stable evidence. Nat Rev Clin Oncol. 2010;7:153–62.
pubmed: 20142816 pmcid: 3427139 doi: 10.1038/nrclinonc.2009.237
Soreide K, Janssen EA, Soiland H, Körner H, Baak JP. Microsatellite instability in colorectal cancer. Br J Surg. 2006;93:395–406.
pubmed: 16555243 doi: 10.1002/bjs.5328
Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26.
pubmed: 20498393 pmcid: 2903323 doi: 10.1200/JCO.2009.27.1825
Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer. 2009;45:365–73.
pubmed: 18722765 doi: 10.1016/j.ejca.2008.07.016
Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773–9.
pubmed: 29355075 doi: 10.1200/JCO.2017.76.9901

Auteurs

Marco Tonello (M)

Unit of Surgical Oncology of the Esophagus and Digestive Tract, Surgical Oncology Department, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

Dario Baratti (D)

Peritoneal Surface Malignancy Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Paolo Sammartino (P)

Cytoreductive Surgery and HIPEC Unit, Department of Surgery "Pietro Valdoni", Sapienza University of Rome, Rome, Italy.

Andrea Di Giorgio (A)

Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Manuela Robella (M)

Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.

Cinzia Sassaroli (C)

Colorectal Surgical Oncology, Abdominal Oncology Department, Fondazione Giovanni Pascale" IRCCS, Naples, Italy.

Massimo Framarini (M)

General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, Italy.

Mario Valle (M)

Peritoneal Malignancies Unit, INT "Regina Elena", Rome, Italy.

Antonio Macrì (A)

Peritoneal Surface Malignancy and Soft Tissue Sarcoma Program, University of Messina, Messina, Italy.

Luigina Graziosi (L)

General and Emergency Surgery Department, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.

Federico Coccolini (F)

General Emergency and Trauma Surgery, Bufalini Hospital, Cesena, Italy.
General Emergency and Trauma Surgery, Pisa University Hospital, Pisa, Italy.

Piero Vincenzo Lippolis (PV)

General and Peritoneal Surgery, Department of Surgery, Hospital University Pisa (AOUP), Pisa, Italy.

Roberta Gelmini (R)

General and Oncological Surgery Unit, AOU of Modena University of Modena and Reggio Emilia, Modena, Italy.

Marcello Deraco (M)

Peritoneal Surface Malignancy Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Daniele Biacchi (D)

Cytoreductive Surgery and HIPEC Unit, Department of Surgery "Pietro Valdoni", Sapienza University of Rome, Rome, Italy.

Francesco Santullo (F)

Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Marco Vaira (M)

Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.

Katia Di Lauro (K)

Department of Advanced Biomedical Sciences, "Federico II" University, Naples, Italy.

Fabrizio D'Acapito (F)

General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì, Italy.

Fabio Carboni (F)

Peritoneal Malignancies Unit, INT "Regina Elena", Rome, Italy.

Giuseppe Giuffrè (G)

Department of Human Pathology in Adult and Developmental Age 'Gaetano Barresi', Section of Pathology, University of Messina, Messina, Italy.

Annibale Donini (A)

General and Emergency Surgery Department, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.

Paola Fugazzola (P)

General Emergency and Trauma Surgery, Bufalini Hospital, Cesena, Italy.

Pinuccia Faviana (P)

Pathological Anatomy III, Laboratory Medicine Department, Hospital University Pisa (AOUP), Pisa, Italy.

Lorena Sorrentino (L)

General and Oncological Surgery Unit, AOU of Modena University of Modena and Reggio Emilia, Modena, Italy.

Antonio Scapinello (A)

Pathology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

Paola Del Bianco (P)

Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

Antonio Sommariva (A)

Unit of Surgical Oncology of the Esophagus and Digestive Tract, Surgical Oncology Department, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy. antonio.sommariva@iov.veneto.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH